Insider Transactions in Q4 2022 at Acrivon Therapeutics, Inc. (ACRV)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 17
2022
|
Chione LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,456,597
+23.73%
|
-
|
|
Nov 17
2022
|
Chione LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
400,000
+9.4%
|
$4,800,000
$12.5 P/Share
|
|
Nov 17
2022
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
1,421,008
+50.0%
|
-
|
|
Nov 17
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
3,389,500
+43.6%
|
$40,674,000
$12.5 P/Share
|
|
Nov 17
2022
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
BUY
Conversion of derivative security
|
Direct |
888,130
+50.0%
|
-
|
|
Nov 14
2022
|
Peter Blume Jensen President and CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
26,707
+7.69%
|
-
|
|
Nov 14
2022
|
Peter Blume Jensen President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,498,240
+18.15%
|
-
|
|
Nov 14
2022
|
Kristina Masson EVP - Business Operations |
BUY
Grant, award, or other acquisition
|
Indirect |
1,498,240
+18.15%
|
-
|
|
Nov 14
2022
|
Kristina Masson EVP - Business Operations |
BUY
Grant, award, or other acquisition
|
Direct |
26,707
+7.69%
|
-
|
|
Nov 14
2022
|
Rasmus Holm Jorgensen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,030
+50.0%
|
-
|
|
Nov 14
2022
|
Eric Devroe Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,383
+38.35%
|
-
|
|
Nov 14
2022
|
Erick Gamelin Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,030
+50.0%
|
-
|